Mr. Speaker, as the hon. member probably is aware, some months ago we created the new marketed health products directorate at Health Canada. We have put additional resources into post-market surveillance to deal with the very issue that the hon. member has raised.
We are very concerned about adverse reactions in relation to drugs or other therapies and products. That is why we have enhanced our ability to do better and more timely surveillance to ensure the safety of the public.